Viral Decay Acceleration™™(VDA)

An Entirely New Approach to the Treatment of Antiviral Infections

Koronis Pharmaceuticals is pioneering the development of a new class of anti-viral therapeutics based on a novel mechanism – Viral Decay Acceleration™™ (VDA).

Unlike other therapeutics that are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation.

Koronis’ lead product candidate, KP-1461, is currently in clinical trials for HIV. In addition, the company has products in development for the treatment of hepatitis C.

There is a growing need for new anti-viral therapeutics. The number of persons in the U.S. living with HIV/AIDS is increasing, and although there are more than 20 approved drugs to treat HIV infection, resistance development affects all of them and is the leading cause of treatment failure. Additionally, in the U.S., an estimated four million people are infected with hepatitis C and there are only a handful of approved drugs available.